Prytime Medical Devices, Inc. Expands Global Market of Life-Saving Medical Device

Tuesday, April 2, 2019 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

Expansion of flagship product ER-REBOA™ Catheter makes global footprint while new distributor model is unveiled

SAN ANTONIO, April 02, 2019 /PRNewswire-PRWeb/ -- Prytime Medical Devices Inc., an innovative medical device company

that designs, develops and commercializes minimally invasive solutions for hemorrhage control, today announced global expansion of their flagship ER-REBOA™ Catheter (Resuscitative Endovascular Balloon Occlusion of the Aorta), and mobilization of distributors in Austria, Belgium, Netherlands, Luxembourg and Australia.

Globalization of the ER-REBOA™ Catheter is part of the company's plan to expand the commercialization in support of physicians, healthcare practitioners and their patients. Designed, developed and researched with the military, the ER-REBOA™ Catheter is a 7 Fr compatible, guidewire free balloon catheter designed to support rapid and immediate hemorrhage control in the emergency and critical care environments.

"Formalizing new distribution channels is another positive step in our global expansion plans," said David Spencer, President and Chief Executive Officer of Prytime Medical Devices. "As a small company, we are proud of the impact our product has made providing medical personnel a tool to stop bleeding." Spencer is co-founder of the medical technology company, and known for his passion for technology commercialization and economic development.

The ER-REBOA™ Catheter was 510(k) cleared by the U.S. Food and Drug Administration in 2015, granted CE Mark approval in 2016, and licensed by Heath Canada in 2017. These approvals opened the door for expansion into the global markets. Today, the ER-REBOA™ Catheter is available to clinicians in more than 15 countries including U.S., Canada, United Kingdom, France and Germany.

"Our company's strategic alliance with distributors expands availability of the ER-REBOA™ Catheter in the global marketplace," said David G. Baer, Ph.D., Vice President of Market Development at Prytime Medical Devices. "We are enthusiastic about our global expansion and are just getting started." The company has plans to expand to other parts of the world where healthcare technology like the ER-REBOA™ Catheter is needed.

With the ER-REBOA™ Catheter, designed for 7 Fr sheath compatibility, the innovative device reduces the need for surgical repair at the access site, while the guidewire free design supports rapid placement of the device. This unique device can help clinicians improve patient care by stopping the bleeding, and allowing time for medical personnel to gain definitive hemorrhage control.

The company's rapid global expansion and alliance with distributors may help save more patients' lives when the ER-REBOA™ Catheter is used within the overall management and resuscitation of the patient.

"We look forward to our partnership with dynamic companies that also believe no one should bleed to death; the sooner you stop bleeding the better," said Spencer.

About Prytime Medical Devices, Inc. Prytime Medical Devices, Inc. designs, develops and commercializes minimally invasive solutions for hemorrhage control. We are proud to be a part of bringing military medical innovation to the civilian marketplace. We believe no one should bleed to death. The sooner you stop bleeding the better. The underlying intellectual property for the ER-REBOA™ Catheter was conceived by experienced military vascular and trauma surgeons, COL. Todd Rasmussen and Dr. Jonathan Eliason, based on lessons learned on the battlefront during combat.

About REBOA Resuscitative Endovascular Balloon Occlusion of the Aorta is a minimally invasive technique using a balloon catheter to temporarily occlude large vessels in support of hemorrhage control. In trauma, hemorrhage is the leading cause of potentially survivable death: Non-compressible truncal hemorrhage is of particular interest, because there are limited clinical options to temporarily occlude large vessels during truncal hemorrhage. Similarly, clinicians report REBOA use in other emergent hemorrhage control situations, such as postpartum hemorrhage, adjunct during surgical procedures, interventional radiology and pre-hospital settings.

 

SOURCE Prytime Medical Devices, Inc



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store